Cancel culture.

Would management of gleason 6 or grade group 1 prostate cancer be different if we didn’t use the “c” word? This evidence-based review is performed to make the argument for removing grade group 1 from the list of distinguished diseases earning the cancer designation. The main point is that grade group 1 disease is clearly a genomically distinact entity from grade group 3+ disease, one that carries <3% risk of extraprostatic extension. What about the risk for nodal or distant mets? Oh, that’s 0%. Once that has sunken in, you may still wonder who the heck cares what you call it. Well, patients do. TBL: Removing the “caner" from grade grade 1 prostate pathology may work to decrease overtreatment. | Labbate, World J Urol 2021